Learned by Reading
In Wikipedia:
Opium poppy cultivation in the United Kingdom does not need a licence; however, a licence is required for those wishing to extract opium for medicinal products.
(Parse)
(S1 (S (S (NP (NP (NN Opium) (JJ poppy) (NN cultivation))
(PP (IN in)
(NP (DT the) (NNP United) (NNP Kingdom))))
(VP (AUX does) (RB not)
(VP (AUX need)
(NP (DT a) (NN licence)))))
(: ;)
(S (ADVP (RB however)) (, ,)
(NP (DT a) (NN licence))
(VP (AUX is)
(VP (VBN required)
(PP (IN for)
(NP (NP (DT those))
(VP (VBG wishing)
(S (VP (TO to)
(VP (VB extract)
(NP (NP (NN opium))
(PP (IN for)
(NP (JJ medicinal) (NNS products))))
(. .)))
In the British National Corpus:
Consumer goods are those “which are ordinarily intended for private use or consumption” but the following are excluded: growing crops, things comprised in land by being attached to it, water, food, feeding stuff or fertiliser, gas supplied by persons authorised under the Gas Act 1986, aircraft (other than hang-gliders) motor vehicles, controlled drugs, licensed medicinal products and tobacco.
(Parse)
(S1 (S (NP (NN Consumer) (NNS goods))
(VP (AUX are)
(NP (NP (NP (DT those)) ('' '')
(SBAR (SBAR (WHNP (WDT which))
(S (VP (AUX are) (ADVP (RB ordinarily))
(VP (VBN intended)
(PP (IN for)
(NP (NP (JJ private) (NN use)) (CC or)
(NP (NN consumption)))))
('' '') (CC but)
(S (NP (DT the) (JJ following))
(VP (AUX are)
(VP (VBN excluded)))
(: :)
(NP (NP (VBG growing) (NNS crops)) (, ,)
(NP (NP (NNS things))
(VP (VBN comprised)
(PP (IN in)
(NP (NN land)))
(PP (IN by)
(S (VP (AUXG being)
(VP (VBN attached)
(PP (TO to)
(NP (PRP it)))
(, ,)
(NP (NP (NN water)) (, ,)
(NP (NN food)) (, ,)
(NP (NN feeding) (NN stuff)) (CC or)
(NP (NN fertiliser)))
(, ,)
(NP (NP (NN gas))
(VP (VBN supplied)
(PP (IN by)
(NP (NP (NNS persons))
(VP (VBN authorised)
(PP (IN under)
(NP (NP (DT the) (NNP Gas) (NNP Act) (CD 1986)) (, ,)
(NP (NP (NNS aircraft)) (PRN (-LRB- -LRB-)
(PP (JJ other) (IN than)
(NP (NNS hang-gliders)))
(-RRB- -RRB-))
(NP (NN motor) (NNS vehicles)) (, ,)
(NP (VBN controlled) (NNS drugs)) (, ,)
(NP (JJ licensed) (JJ medicinal) (NNS products)) (CC and)
(NP (NN tobacco))))
(. .)))
In Wikipedia:
No known interaction with other medicinal products.
(Parse)
(S1 (NP (NP (DT No) (JJ known) (NN interaction))
(PP (IN with)
(NP (JJ other) (JJ medicinal) (NNS products)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The European Court of Justice has said that if a dominant company refused to meet ‘ordinary’ orders for medicinal products in order to stop’ parallel exports ’, it was breaching EU competition law
(Parse)
(S1 (S (NP (NP (DT The) (NNP European) (NNP Court))
(PP (IN of)
(NP (NNP Justice))))
(VP (AUX has)
(VP (VBD said)
(SBAR (IN that)
(S (SBAR (IN if)
(S (NP (DT a) (JJ dominant) (NN company))
(VP (VBD refused)
(S (VP (TO to)
(VP (VB meet) ('' ')
(NP (NP (JJ ordinary) ('' ') (NNS orders))
(PP (IN for)
(NP (JJ medicinal) (NNS products))))
(SBAR (IN in) (NN order)
(S (VP (TO to)
(VP (VB stop) ('' ')
(NP (JJ parallel) (NNS exports)) ('' ')))))
(, ,)
(NP (PRP it))
(VP (AUX was)
(VP (VBG breaching)
(NP (JJ EU) (NN competition) (NN law))))))))))
In Wikipedia:
The Good Clinical Practice Directive (Directive 2005 / 28 / EC of 8 April 2005 of the European Parliament and of the Council) lays down principles and detailed guidelines for good clinical practice as regards conducting clinical trials of medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products.
(Parse)
(S1 (S (NP (NP (DT The) (JJ Good) (JJ Clinical) (NN Practice) (NN Directive)) (PRN (-LRB- -LRB-)
(NP (NP (NN Directive) (CD 2005) (NNP /) (CD 28) (NNP /) (NNP EC))
(PP (PP (IN of)
(NP (NP (CD 8) (NNP April) (CD 2005))
(PP (IN of)
(NP (DT the) (NNP European) (NNP Parliament)))))
(CC and)
(PP (IN of)
(NP (DT the) (NNP Council)))))
(-RRB- -RRB-)))
(VP (VBZ lays) (PRT (RP down))
(NP (NP (NNS principles)) (CC and)
(NP (NP (JJ detailed) (NNS guidelines))
(PP (IN for)
(NP (JJ good) (JJ clinical) (NN practice)))))
(SBAR (IN as)
(S (VP (VBZ regards)
(S (VP (VBG conducting)
(NP (NP (NP (JJ clinical) (NNS trials))
(PP (IN of)
(NP (NP (JJ medicinal) (NNS products))
(PP (IN for)
(NP (JJ human) (NN use)))
(, ,) (CONJP (RB as) (RB well) (IN as))
(NP (NP (DT the) (NNS requirements))
(PP (IN for)
(NP (NP (NN authorisation))
(PP (IN of)
(NP (NP (DT the) (NN manufacturing) (CC or) (NN importation))
(PP (IN of)
(NP (JJ such) (NNS products)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
A team of researchers, led by Dr. Robert Saper, at Boston University School of Medicine in Massachusetts bought 193 medicinal products, made by 37 different manufacturers in both India and the US.
(Parse)
(S1 (S (NP (NP (DT A) (NN team))
(PP (IN of)
(NP (NNS researchers)))
(, ,)
(VP (VBN led)
(PP (IN by)
(NP (NNP Dr.) (NNP Robert) (NNP Saper))))
(, ,))
(PP (IN at)
(NP (NP (NNP Boston) (NNP University) (NNP School))
(PP (IN of)
(NP (NNP Medicine)))
(PP (IN in)
(NP (NNP Massachusetts)))))
(VP (VBD bought)
(NP (NP (CD 193) (JJ medicinal) (NNS products)) (, ,)
(VP (VBN made)
(PP (IN by)
(NP (CD 37) (JJ different) (NNS manufacturers)))))
(PP (IN in)
(NP (PDT both)
(NP (NNP India)) (CC and)
(NP (DT the) (NNP US)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long – acting Injection (LAI), known in Europe by the trade name Zypadhera (TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today.
(Parse)
(S1 (S (S (NP (NP (DT The) (NNP Committee))
(PP (IN for)
(NP (JJ Medicinal) (NNS Products)))
(PP (IN for)
(NP (NP (NNP Human) (NNP Use)) (PRN (-LRB- -LRB-)
(NP (NNP CHMP)) (-RRB- -RRB-)))))
(VP (AUX has)
(VP (VBN recommended)
(NP (NNP European) (NN approval))
(PP (IN of)
(NP (NNP Olanzapine) (NNP Long)))
(: -)
(NP (NP (NP (JJ acting) (NN Injection)) (PRN (-LRB- -LRB-)
(NP (NNP LAI)) (-RRB- -RRB-)) (, ,)
(VP (VBN known)
(PP (IN in)
(NP (NNP Europe)))
(PP (IN by)
(NP (NP (DT the) (NN trade) (NN name))
(NP (NP (NNP Zypadhera)) (PRN (-LRB- -LRB-)
(NP (NNP TM)) (-RRB- -RRB-)))
(, ,))
(PP (IN for)
(NP (NP (NN maintenance) (NN treatment))
(PP (IN of)
(NP (NP (JJ adult) (NNS patients))
(PP (IN with)
(NP (NN schizophrenia))))
(VP (ADVP (RB sufficiently)) (VBN stabilized)
(PP (IN during)
(NP (JJ acute) (NN treatment)))
(PP (IN with)
(NP (JJ oral) (NN olanzapine)))))
(, ,)
(NP (NP (NNP Eli) (NNP Lilly)) (CC and)
(NP (NP (NNP Company)) (PRN (-LRB- -LRB-)
(NP (NNP LLY)) (-RRB- -RRB-))))
(VP (VBD announced)
(NP (NN today)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the product information for Tysabri (natalizumab) be updated to further increase awareness about the risk of progressive multifocal leukoencephalopathy (PML) in patients with relapsing – remitting multiple sclerosis (MS) who have been treated with the medicine.
(Parse)
(S1 (S (NP (NP (NP (DT The) (NNP European) (NNP Medicines) (NNP Agency) (POS 's)) (NNP Committee))
(PP (IN for)
(NP (NP (JJ Medicinal) (NNS Products))
(PP (IN for)
(NP (JJ Human) (NN Use)))))
(PRN (-LRB- -LRB-)
(NP (NNP CHMP)) (-RRB- -RRB-)))
(VP (AUX has)
(VP (VBN recommended)
(PP (IN that)
(NP (DT the) (NN product) (NN information)))
(PP (IN for)
(S (NP (NNP Tysabri)) (PRN (-LRB- -LRB-) (NN natalizumab) (-RRB- -RRB-)
(VP (AUX be)
(VP (VBN updated)
(S (VP (TO to)
(VP (VB further)
(S (VP (VB increase)
(NP (NP (NN awareness))
(PP (IN about)
(NP (NP (DT the) (NN risk))
(PP (IN of)
(NP (JJ progressive) (JJ multifocal) (NN leukoencephalopathy)))
(PRN (-LRB- -LRB-)
(NP (NNP PML)) (-RRB- -RRB-)))))
(PP (IN in)
(NP (NP (NNS patients))
(PP (IN with)
(NP (NN relapsing)))
(: -))
(VP (VBG remitting)
(NP (NP (JJ multiple) (NN sclerosis)) (PRN (-LRB- -LRB-) (NN MS) (-RRB- -RRB-))
(SBAR (WHNP (WP who))
(S (VP (AUX have)
(VP (AUX been)
(VP (VBN treated)
(PP (IN with)
(NP (DT the) (NN medicine)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Clinical trials in canada has e mportant industry reference source to find out more, or to receive a free focused on cure – all medicinal products, eg broadband.
(Parse)
(S1 (S (NP (NP (JJ Clinical) (NNS trials))
(PP (IN in)
(NP (NNP canada))))
(VP (AUX has)
(S (NP (NNP e) (JJ mportant) (NN industry) (NN reference) (NN source))
(VP (VP (TO to)
(VP (VB find) (PRT (RP out))
(NP (JJR more))))
(, ,) (CC or)
(VP (TO to)
(VP (VB receive)
(NP (NP (NP (DT a) (JJ free))
(VP (VBN focused)
(PP (IN on)
(NP (NN cure)))))
(: -)
(NP (DT all) (JJ medicinal) (NNS products)) (, ,)
(ADJP (RB eg) (JJ broadband)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Under French Law, pharmacies benefit from a monopoly on the sale of medicinal products.
(Parse)
(S1 (S (PP (IN Under)
(NP (NNP French) (NN Law)))
(, ,)
(NP (NNS pharmacies))
(VP (VB benefit)
(PP (IN from)
(NP (NP (DT a) (NN monopoly))
(PP (IN on)
(NP (NP (DT the) (NN sale))
(PP (IN of)
(NP (JJ medicinal) (NNS products)))))
(. .)))
In Wikipedia:
Based in London, the EMEA was born after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products set up in 1977 and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees.
(Parse)
(S1 (S (S (VP (VBN Based)
(PP (IN in)
(NP (NNP London)))))
(, ,)
(NP (DT the) (NN EMEA))
(VP (AUX was)
(VP (VP (VBN born)
(PP (IN after)
(NP (NP (QP (JJR more) (IN than) (CD seven)) (NNS years))
(PP (IN of)
(NP (NP (NNS negotiations))
(PP (IN among)
(NP (JJ EU) (NNS governments)))))
(CC and)
(VP (VBN replaced)
(NP (NP (NP (DT the) (NNP Committee))
(PP (IN for)
(NP (JJ Proprietary) (JJ Medicinal) (NNS Products)))
(VP (VBD set) (PRT (RP up))
(PP (IN in)
(NP (CD 1977)))))
(CC and)
(NP (NP (DT the) (NNP Committee))
(PP (IN for)
(NP (JJ Veterinary) (JJ Medicinal) (NNS Products)))))
(, ,)
(SBAR (IN though)
(S (NP (NP (DT both))
(PP (IN of)
(NP (DT these))))
(VP (AUX were)
(ADJP (JJ reborn)
(PP (IN as)
(NP (DT the) (JJ core) (JJ scientific) (JJ advisory) (NNS committees))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
According to the guidelines of the European Agency for the Evaluation of Medicinal products (EMEA), extensive comparability testing will be required to demonstrate that the biosimilar has a comparable profile in terms of quality, safety and efficacy as the reference product.
(Parse)
(S1 (S (PP (VBG According)
(PP (TO to)
(NP (NP (DT the) (NNS guidelines))
(PP (IN of)
(NP (NP (DT the) (NNP European) (NNP Agency))
(PP (IN for)
(NP (NP (DT the) (NN Evaluation))
(PP (IN of)
(NP (JJ Medicinal) (NNS products)))))
(PRN (-LRB- -LRB-)
(NP (NNP EMEA)) (-RRB- -RRB-))))
(, ,)
(NP (JJ extensive) (NN comparability) (NN testing))
(VP (MD will)
(VP (AUX be)
(VP (VBN required)
(S (VP (TO to)
(VP (VB demonstrate)
(SBAR (IN that)
(S (NP (DT the) (NN biosimilar))
(VP (AUX has)
(NP (DT a) (JJ comparable) (NN profile))
(PP (IN in)
(NP (NP (NNS terms))
(PP (IN of)
(NP (NN quality) (, ,) (NN safety) (CC and) (NN efficacy)))))
(PP (IN as)
(NP (DT the) (NN reference) (NN product)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
CHMP Recommends Approval of Olanzapine Long – acting Injection for Maintenance Treatment of Schizophrenia in Europe INDIANAPOLIS, September 26, 2008 / PRNewswire – FirstCall / – The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long – acting Injection (LAI), known in Europe by the trade name Zypadhera (TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today.
(Parse)
(S1 (S (S (NP (NNP CHMP))
(VP (VBZ Recommends)
(NP (NP (NN Approval))
(PP (IN of)
(NP (NNP Olanzapine) (NNP Long)))
(: -)
(S (NP (NP (JJ acting) (NN Injection))
(PP (IN for)
(NP (NN Maintenance) (NN Treatment)))
(PP (IN of)
(NP (NP (NN Schizophrenia))
(PP (IN in)
(NP (NP (NNP Europe) (NNP INDIANAPOLIS)) (, ,)
(NP (NP (NNP September) (CD 26) (, ,) (CD 2008)) (NNP /) (NNP PRNewswire) (: -) (NNP FirstCall) (NNP /)) (: --)
(NP (NP (DT The) (NNP Committee))
(PP (IN for)
(NP (JJ Medicinal) (NNS Products)))
(PP (IN for)
(NP (NP (NNP Human) (NNP Use)) (PRN (-LRB- -LRB-)
(NP (NNP CHMP)) (-RRB- -RRB-))))
(VP (AUX has)
(VP (VBN recommended)
(NP (NNP European) (NN approval))
(PP (IN of)
(NP (NNP Olanzapine) (NNP Long)))
(: -)
(S (VP (VBG acting)
(NP (NP (NN Injection)) (PRN (-LRB- -LRB-)
(NP (NNP LAI)) (-RRB- -RRB-)) (, ,)
(VP (VBN known)
(PP (IN in)
(NP (NNP Europe)))
(PP (IN by)
(NP (NP (DT the) (NN trade) (NN name))
(NP (NP (NNP Zypadhera)) (PRN (-LRB- -LRB-)
(NP (NNP TM)) (-RRB- -RRB-)))
(, ,))
(PP (IN for)
(NP (NP (NN maintenance) (NN treatment))
(PP (IN of)
(NP (NP (NN adult) (NNS patients))
(PP (IN with)
(S (NP (NN schizophrenia))
(VP (ADVP (RB sufficiently)) (VBN stabilized)
(PP (IN during)
(NP (NP (JJ acute) (NN treatment))
(PP (IN with)
(NP (NP (JJ oral) (NN olanzapine)) (, ,)
(NP (NP (NNP Eli) (NNP Lilly) (CC and) (NNP Company)) (PRN (-LRB- -LRB-) (RB LLY) (-RRB- -RRB-))
(VP (VBD announced)
(NP (NN today)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Before June 2008, melatonin was only available in the UK in unlicensed medicinal products, many of which were non – pharmaceutical grade products imported from the United States of America, where melatonin products are classed as supplements, not medicines.
(Parse)
(S1 (S (PP (IN Before)
(NP (NNP June) (CD 2008)))
(, ,)
(NP (NN melatonin))
(VP (AUX was)
(ADJP (RB only) (JJ available))
(PP (IN in)
(NP (DT the) (NNP UK)))
(PP (IN in)
(NP (NP (JJ unlicensed) (JJ medicinal) (NNS products)) (, ,)
(ADJP (JJ many)
(PP (IN of)
(SBAR (WHNP (WDT which))
(S (VP (AUX were)
(NP (NP (NN non)) (: -)
(NP (NP (JJ pharmaceutical) (NN grade) (NNS products))
(VP (VBN imported)
(PP (IN from)
(NP (NP (DT the) (NNP United) (NNPS States))
(PP (IN of)
(NP (NNP America)))
(, ,)
(SBAR (WHADVP (WRB where))
(S (NP (JJ melatonin) (NNS products))
(VP (AUX are)
(VP (VBN classed)
(PP (IN as)
(NP (NP (NNS supplements)) (, ,) (RB not)
(NP (NNS medicines)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Prescription medicinal products may only be distributed through pharmacies upon medical prescription however, only few herbal medicinal products are prescription – bound.
(Parse)
(S1 (S (NP (NN Prescription) (NN medicinal) (NNS products))
(VP (MD may) (ADVP (RB only))
(VP (VB be)
(VP (VBN distributed)
(PP (IN through)
(NP (NNS pharmacies)))
(PP (IN upon)
(NP (JJ medical) (NN prescription)))
(SBAR (S (ADVP (RB however)) (, ,)
(NP (QP (RB only) (JJ few)) (JJ herbal) (JJ medicinal) (NNS products))
(VP (VBP are)
(NP (NP (NN prescription)) (: -)
(VP (VBN bound)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Tramadol ultram medicine dose of tramadol in dogs both vaccines require further evaluation of medicinal products, acidophilus is available growth charts tramadol hcl mg tablet.
(Parse)
(S1 (S (NP (NP (JJ Tramadol) (NN ultram) (NN medicine) (NN dose))
(PP (IN of)
(NP (NP (NN tramadol))
(PP (IN in)
(NP (NP (NNS dogs))
(SBAR (S (NP (DT both) (NNS vaccines))
(VP (VBP require)
(NP (NP (JJ further) (NN evaluation))
(PP (IN of)
(NP (JJ medicinal) (NNS products)))
(, ,)
(ADJP (JJ acidophilus)))))
(VP (VBZ is)
(NP (NP (ADJP (JJ available)) (NN growth) (NNS charts))
(ADJP (JJ tramadol)
(NP (QP (CD hcl) (CD mg)) (NN tablet)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
For example when acting on the behalf for medicinal products, celebrities aren’t the drug testing department, if the manufacturer got a drug test permit then the they are only able to think that the product ought to be legitimate.
(Parse)
(S1 (S (PP (IN For)
(NP (NN example)))
(SBAR (WHADVP (WRB when))
(S (VP (VBG acting)
(PP (IN on)
(NP (NP (DT the) (NN behalf))
(PP (IN for)
(NP (JJ medicinal) (NNS products)))))
(, ,)
(NP (NNS celebrities))
(VP (AUX are) (RB n't)
(NP (DT the) (NN drug) (NN testing) (NN department)) (, ,)
(SBAR (IN if)
(S (NP (DT the) (NN manufacturer))
(VP (VBD got)
(NP (DT a) (NN drug) (NN test) (NN permit)) (ADVP (RB then))
(SBAR (DT the)
(S (NP (PRP they))
(VP (VBP are) (ADVP (RB only))
(ADJP (JJ able)
(S (VP (TO to)
(VP (VB think)
(SBAR (IN that)
(S (NP (DT the) (NN product))
(VP (MD ought)
(S (VP (TO to)
(VP (AUX be)
(ADJP (JJ legitimate))))
(. .)))
In Wikipedia:
Besides medicinal products for gastroenterology and migraine / pain, pulmology become the focal point of the preparations programme.
(Parse)
(S1 (S (PP (IN Besides)
(NP (NP (JJ medicinal) (NNS products))
(PP (IN for)
(NP (NN gastroenterology) (CC and) (NN migraine) (NNS /) (NN pain)))))
(, ,)
(NP (NNS pulmology))
(VP (VBP become)
(NP (NP (DT the) (JJ focal) (NN point))
(PP (IN of)
(NP (DT the) (NNS preparations) (NN programme)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The two cases are currently being assessed by the EMEA’s scientific Committee for Medicinal Products for Human Use (CHMP).
(Parse)
(S1 (S (NP (DT The) (CD two) (NNS cases))
(VP (VBP are) (ADVP (RB currently))
(VP (VBG being)
(VP (VBN assessed)
(PP (IN by)
(NP (NP (DT the) (NNP EMEA) (POS 's)) (JJ scientific) (NN Committee)))
(PP (IN for)
(NP (NP (JJ Medicinal) (NNS Products))
(PP (IN for)
(NP (JJ Human) (NN Use)))
(PRN (-LRB- -LRB-) (NN CHMP) (-RRB- -RRB-))))
(. .)))
And 185 more sentences.